# What role does LL-37 play in managing oral biofilm infections?

Canonical source: https://retacompare.com/research/what-role-does-ll-37-play-in-managing-oral-biofilm-infections

Peptide Longevity Q&A · 2026-04-29


    Research indicates that LL-37 is an antimicrobial peptide secreted by dental pulp stem cells (DPSCs), which helps control oral biofilm infections by disrupting pathogenic bacteria like Porphyromonas gingivalis. This peptide also supports inflammation resolution and tissue regeneration.

 What the research shows

The review synthesizes evidence from 2000 to 2025 regarding the properties of dental pulp stem cells (DPSCs) in managing plaque biofilm-associated infections. The authors systematically reviewed literature focusing on DPSCs, oral biofilms, and antimicrobial peptides, including LL-37. DPSCs exhibit a dual-function strategy in combating infections: they secrete antimicrobial peptides that directly target harmful bacteria, such as Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans, while also facilitating the resolution of inflammation through mechanisms like macrophage M2 polarization and suppression of pro-inflammatory cytokines like IL-1β and TNF-α. This review highlights the potential of DPSCs, and by extension, LL-37, as antibiotic-sparing therapeutic candidates for managing gingivitis and oral biofilm infections.

 Why it matters for longevity

The findings regarding LL-37 and DPSCs are significant in the context of longevity and healthspan. Chronic oral infections and inflammation can contribute to systemic health issues, including cardiovascular diseases and diabetes, which are associated with aging. By effectively managing oral biofilm infections and promoting tissue regeneration, LL-37 may play a role in mitigating these risks, potentially enhancing overall health and longevity. Moreover, the immunomodulatory effects of LL-37 could help maintain a balanced immune response, which is crucial for healthy aging.

 Key findings at a glance

LL-37 is an antimicrobial peptide secreted by dental pulp stem cells (DPSCs).

DPSCs help control oral biofilm infections by targeting specific pathogenic bacteria.

LL-37 supports the resolution of inflammation through immune modulation.

DPSCs facilitate periodontal tissue regeneration.

No clinical trials have yet evaluated DPSCs for managing gingivitis.

LL-37 may serve as an antibiotic-sparing therapeutic candidate.

 How LL-37 works (background)

LL-37 is a cathelicidin antimicrobial peptide that plays a crucial role in the innate immune response. It exerts its antimicrobial effects by disrupting bacterial cell membranes, leading to cell lysis and death. In addition to its direct antimicrobial activity, LL-37 has immunomodulatory properties, influencing various immune cells and promoting a shift towards anti-inflammatory responses. This dual action makes LL-37 a promising candidate for therapeutic applications in managing infections and inflammation, particularly in the oral cavity.

 Safety, caveats, and what we don't yet know

While the review highlights the potential benefits of LL-37 and DPSCs in managing oral biofilm infections, there are limitations to the current research. Most findings are preclinical and have not been validated in clinical trials. Additionally, the long-term safety and efficacy of using DPSCs or LL-37 in human subjects remain unclear. Future studies are needed to address these gaps and explore the full potential of LL-37 in various populations, particularly in older adults who may be more susceptible to oral infections and related systemic health issues.

 Bottom line

In summary, LL-37 plays a significant role in managing oral biofilm infections through its antimicrobial and immunomodulatory properties. Its potential as an antibiotic-sparing therapeutic candidate highlights its relevance in the context of healthspan and longevity.

 Related questions

 Can LL-37 enhance tissue regeneration in aging individuals?

Research suggests that LL-37 may support tissue regeneration through its effects on dental pulp stem cells, which could be beneficial in older populations facing regenerative challenges.

 Does LL-37 have a role in oral health and systemic diseases?

Yes, LL-37's antimicrobial and anti-inflammatory properties may help manage oral infections that are linked to systemic diseases, which is particularly important for aging individuals.

 What are the implications of LL-37 for chronic inflammation?

LL-37 may help resolve chronic inflammation by modulating immune responses, which is crucial for maintaining health and preventing age-related diseases.

 Source: PubMed · Int Dent J · published 2026-04-29.

## Sources

- PubMed · Int Dent J: https://pubmed.ncbi.nlm.nih.gov/42061103/